StratumSkin science, cited
CHolistic health·11 min·6 sources

Skin supplements: the few that hold up, and the many that don't

One has genuinely strong evidence. One we have just downgraded. One is worth avoiding before a blood test. The rest are expensive urine.

Disclosure

Nothing here is sponsored and we earn nothing from anything mentioned. If that ever changes, this box will say so before you read a word of the article.

Evidence at a glance

Collagen peptides
C Effect vanishes in independently funded trials. Downgraded from B.
Nicotinamide tablets
A Strong evidence for people at high skin cancer risk.
Omega-3
C Plausible, and one real RCT found benefit for acne, but results across the wider literature are genuinely mixed.
Zinc
C Real but dated trial evidence, weaker than standard treatments, and the effective dose tends to cause nausea.
Biotin
D No benefit unless deficient, and it skews blood tests.

The supplement aisle is where good evidence goes to be quoted out of context. Almost every bottle can point to a study. Very few can point to a good one, and fewer still to a good one that wasn't paid for by the company selling the bottle.

Here's the honest sorting.

The one with genuinely strong evidence, for a specific group

Nicotinamide, taken as a tablet at 500 mg twice daily, reduced new skin cancers in a large randomised trial of people who had already had several. That's a proper Grade A result with a hard clinical endpoint.

The catch is who it's for. The trial recruited people at high risk, and the benefit was measured in that population. If you've never had a skin cancer, this trial doesn't tell you much about your odds, and it's a conversation to have with a dermatologist rather than a supermarket shelf.

The one we got wrong, and had to downgrade

Collagen peptides were, for years, easy to mock. Eat collagen, digest it into amino acids like any other protein, achieve nothing: that was the reasonable prediction.

The trials appeared not to cooperate. A 2021 review pooled the clinical trials together and found improvements in skin hydration and elasticity. On that basis we originally graded collagen B, and said so.

Then a 2025 meta-analysis did something the earlier ones had not: it sorted the 23 trials by who paid for them. Pooled together, the benefit was still there. Split apart, trials funded by supplement companies showed clear benefits. Trials without industry funding showed no effect on hydration, elasticity or wrinkles. None. The same split appeared when studies were sorted by methodological quality instead of funding. And a third cut, simply removing the handful of trials reporting extreme results, wiped out the wrinkle benefit on its own.

So we have downgraded collagen peptides from B to C. The positive signal is real, and it lives almost entirely in trials run by people who sell collagen. Collagen manufacturers have publicly disputed how that analysis sorted the trials. They point out that 21 of the 23 had industry involvement of some kind, so the “independent” pile was small. That's a fair criticism of the labels, and an awkward one to lean on, because it concedes that almost the entire evidence base was paid for by people selling collagen.

This is what grading is for. A number that moves the moment someone checks who paid for the research was never a solid number.

The plausible ones

Omega-3 fatty acids have reasonable mechanistic logic and genuinely mixed human results in acne and psoriasis. A 2014 randomised, double-blind trial found real improvement in acne from omega-3 plus gamma-linolenic acid supplementation. But it sits alongside other trials finding nothing, which is the honest state of this evidence: some trials find benefit, some don't. If you eat very little oily fish, supplementing is sensible for reasons that have nothing to do with your face.

Zinc has real, if modest, acne evidence. An older double-blind trial found it beat placebo, though it's generally weaker than standard treatments and generally dosed at levels that cause nausea. It also competes with copper absorption over the long term. It's a reasonable adjunct, not a plan.

Please read this one

High-dose biotin, the hair, skin and nails staple, does nothing for skin unless you have a genuine deficiency, which is rare. More importantly, it interferes with a wide range of common laboratory blood tests, including thyroid function and the troponin test used to diagnose heart attacks. The US Food and Drug Administration has warned about this twice, and says it kept receiving reports of falsely low troponin results after the first warning. If you take biotin, tell whoever draws your blood, and stop several days before any planned test.

The ones with nothing behind them

Marine collagen marketed as superior to bovine, "beauty waters", chlorophyll drops, and most multi-ingredient beauty gummies fall into a category we'd describe as Grade D at best: a plausible-sounding mechanism, no human trial, and a price that assumes you won't check.

Gummies deserve a specific mention. To taste acceptable they need sugar, and to fit in a gummy the active doses are usually well below anything ever tested.

The short version

Eat properly. If you've had multiple skin cancers, ask a dermatologist about nicotinamide. Collagen peptides are defensible if you have spare money and modest expectations. Tell your doctor about biotin. Everything else can wait until someone runs a trial that isn't funded by the people selling it.

This is general education, not medical advice. Nothing here accounts for your history, your medication or your skin, and none of it replaces assessment by a qualified clinician. Where we describe what research found, that is a description of a study — not a promise about you.

Revision history

  • Collagen peptides B→CDowngraded collagen peptides from Grade B to Grade C after a 2025 meta-analysis sorted the existing trials by funding source: pooled together, the benefit looked real, but split apart, independently funded and higher-quality trials showed no effect on hydration, elasticity or wrinkles. The glance table, body text and grade were all updated to reflect this.

References

  1. Chen AC, Martin AJ, Choy B, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. New England Journal of Medicine, 2015.APhase 3 RCT, n=386, 12 months·High-risk population only, because everyone enrolled had already had at least two skin cancersPubMed 26488693DOI 10.1056/NEJMoa1506197
  2. de Miranda RB, Weimer P, Rossi RC. Effects of hydrolyzed collagen supplementation on skin aging: a systematic review and meta-analysis. International Journal of Dermatology, 2021.BSystematic review and meta-analysis of clinical trials·Pooled all trials together without separating by funding sourcePubMed 33742704DOI 10.1111/ijd.15518
  3. Myung SK, Park Y. Effects of collagen supplements on skin aging: a systematic review and meta-analysis of randomized controlled trials. The American Journal of Medicine, 2025.AMeta-analysis of 23 RCTs, n=1,474·Authors declared no funding and no conflict of interest. Pooled across all 23 trials the benefit was significant, but it vanished in non-industry-funded trials, in high-quality trials, and when outlier trials were removed. Industry critics note 21 of 23 trials had some industry involvement.PubMed 40324552DOI 10.1016/j.amjmed.2025.04.034
  4. Jung JY, Kwon HH, Hong JS, Yoon JY, Park MS, Jang MY, Suh DH. Effect of Dietary Supplementation with Omega-3 Fatty Acid and Gamma-linolenic Acid on Acne Vulgaris: A Randomised, Double-blind, Controlled Trial. Acta Dermato-Venereologica, 2014.CRandomised, double-blind, controlled trial·Found real improvement in acne lesion counts with omega-3 plus gamma-linolenic acid supplementation. One supporting trial in a field where other trials have found no effect. That's genuinely mixed evidence, not a settled case.PubMed 24553997DOI 10.2340/00015555-1802
  5. U.S. Food and Drug Administration. UPDATE: the FDA warns that biotin may interfere with lab tests — FDA safety communication. FDA Safety Communication, 5 November 2019, 2019.BRegulatory safety communication·Follows the original 2017 communication. FDA continued receiving reports of falsely low troponin resultsRead the source
  6. Verma KC, Saini AS, Dhamija SK. Oral zinc sulphate therapy in acne vulgaris: a double-blind trial. Acta Dermato-Venereologica, 1980.CDouble-blind controlled trial·Older trial. Zinc sulphate beat placebo, but the effect was more modest and slower to appear than standard acne treatments, and the effective dose is the one that tends to cause nausea.PubMed 6163281

Related condition hub

Acne

Your turn

Did this hold up? Tell us honestly — especially if it didn’t.

Anonymous. Stored in your browser.

The Sunday study

One paper a week, explained properly

We pick a single new study, tell you what it measured, how many people it measured it in, and whether it should change anything you're doing — plus the two articles we published that week. No panic, and no hype.

We don't recommend products yet. When we do, they'll be things you can actually buy in India, any affiliate link will be labelled as one, and a commission will never buy a recommendation.

One email each Sunday. Unsubscribe in one click.